


Deep Pharma Intelligence


Artificial Intelligence in Oncology 2023

Introducing AI in Oncology, a cutting-edge platform powered by advanced artificial intelligence, designed to revolutionize oncology research and treatment. With a firm belief in the power of AI to transform the medical landscape, **Deep Pharma Intelligence** proudly presents this groundbreaking platform that holds the key to unlocking new frontiers in cancer care.





Asia regions with 16.6 and 11.6% of all AI companies included into analysis. Interestingly, UK holds the 4th place, placing 6% of companies, all of which were founded from 2015 to 2019. In contrast, the oldest and the newest companies, are located in the United States. As well as top 10 largest last funding amounts come from US. Thus US is maintaining the status of AI in Oncology Leadership. Meanwhile, Israel and Canada hold less than 5% each. Another 5% are distributed around other regions.



Experts in the field of AI in Oncology

At the forefront of Al-driven oncology, a diverse team of experts, including researchers, data scientists, and technologists, is dedicated to harnessing Al's potential to address the complex challenges of oncology drugs R&D. Together, they strive to unlock groundbreaking innovations that could revolutionize cancer treatment.



Learn More

Become a Partner

Source: www.deep-pharma.tech/oncology-ai

Al in Drug Discovery Analytical Dashboard

The AI in Drug Discovery Analytical Dashboard is a fundamental tool offering strategic insights, opportunity evaluation, competitor profiling, and other functions relevant to Pharma and BioTech decision-makers, life science investors, consulting companies, and regulatory agencies.

800	Companies
1,900	Investors
265	R&D Collaborations
3200	Clinical Trials
170	Parameters of Automated SWOT Analysis
Market Intelligence Focus	
	Automated Interactive Chart Builder

Source: www.deep-pharma.tech/ai-platform

www.deep-pharma.tech